1990’s Publications


  1. Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, Lemaistre FC, Smallwood L, Pruitt K, Dixon DO. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.Blood, 1990 Nov 1;76(9);1860-6. PMID: 2224133
  2. Alexanian R, Barlogie B. New treatment strategies for multiple myeloma. Am J Hematol, 1990 Nov;35(3);194-8. PMID: 2220763
  3. Barlogie B, Jagannath S, Dixon DO, Cheson B, Smallwood L, Hendrickson A, Purvis JD, Bonnem E, Alexanian R.High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood, 1990 Aug 15;76(4);677-80. PMID: 2200536
  4. Bergsagel DE, von Wussow P, Alexanian R, Avvisati G, Bataille R, Barlogie B, Borden E, Caligaris-Cappio F, Deicher H, Durie BG. Interferons in the treatment of multiple myeloma. J Clin Oncol, 1990 Aug;8(8);1444-5.PMID: 2380763
  5. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med, 1990 Aug;150(8);1693-5. PMID: 2383164
  6. Ventura GJ, Barlogie B, Hester JP, Yau JC, LeMaistre CF, Wallerstein RO, Spinolo JA, Dicke KA, Horwitz LH, Alexanian R. High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma. Bone Marrow Transplant, 1990 Apr;5(4);265-8. PMID: 1970939
  7. Barlogie B. Diagnosis and treatment of high-grade myeloma. Am J Med, 1990 Apr;88(4);445-6. PMID: 2327436
  8. Epstein J, Xiao HQ, He XY. Markers of multiple hematopoietic-cell lineages in multiple myeloma. N Engl J Med, 1990 Mar 8;322(10);664-8. PMID: 2137556
  9. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol, 1990 Feb;33(2);86-9. PMID: 2301376
  10. Barlogie B. Management of multiple myeloma. Blut, 1990 Jan;60(1);1-7. PMID: 2404526
  11. Barlogie B, Epstein J. Multiple myeloma: biology and therapy. J Cancer Res Clin Oncol, 1990;116(1);109-11.PMID: 2312600


  1. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med, 1991 Dec 15;115(12);931-5. PMID: 1952489
  2. Barlogie B. Toward a cure for multiple myeloma? N Engl J Med, 1991 Oct 31;325(18);1304-6. PMID: 1922227
  3. Salmon SE, Beckord J, Pugh RP, Barlogie B, Crowley J. alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study. Semin Oncol, 1991 Oct;18(5 Suppl 7);33-6.PMID: 1948127
  4. Barlogi B, Epstein J, Selvaniagam P, Alexanian R. [Plasma cell myeloma. I. A new concept of disease biology]Gematol Transfuziol, 1991 Aug;36(8);29-35. PMID: 1752407
  5. Alexanian R, Barlogie B, Gutterman J. Alpha-interferon combination therapy of resistant myeloma. Am J Clin Oncol, 1991 Jun;14(3);188-92. PMID: 2031504
  6. Barlogie B, Gahrton G. Bone marrow transplantation in multiple myeloma. Bone Marrow Transplant, 1991 Feb;7(2);71-9. PMID: 2049563


  1. Barlogie B, Alexanian R, Jagannath S. Plasma cell dyscrasias. JAMA, 1992 Nov 25;268(20);2946-51. PMID: 1433713
  2. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood, 1992 Oct 1;80(7);1666-72.PMID: 1391937
  3. Barlogie B, Gale RP. Multiple myeloma and chronic lymphocytic leukemia: parallels and contrasts. Am J Med, 1992 Oct;93(4);443-50. PMID: 1415309
  4. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood, 1992 Aug 15;80(4);887-90. PMID: 1498331
  5. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. [Plasma-cell myeloma. II. New developments in the diagnosis and treatment of the disease] Gematol Transfuziol, 1992 Jul-Aug;37(7-8);33-9. PMID: 1342986
  6. Kreitman RJ, Siegall CB, FitzGerald DJ, Epstein J, Barlogie B, Pastan I. Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood, 1992 Apr 1;79(7);1775-80. PMID: 1558971
  7. Epstein J. Myeloma phenotype: clues to disease origin and manifestation. Hematol Oncol Clin North Am, 1992 Apr;6(2);249-56. PMID: 1582972
  8. Jagannath S, Barlogie B. Autologous bone marrow transplantation for multiple myeloma. Hematol Oncol Clin North Am, 1992 Apr;6(2);437-49. PMID: 1582984
  9. Barlogie B, Jagannath S. Autotransplants in myeloma. Bone Marrow Transplant, 1992;10 Suppl 137-44. PMID: 1355685
  10. Thomas X, Xiao HQ, Chang R, Epstein J. Circulating B lymphocytes in multiple myeloma patients contain an autocrine IL-6 driven pre-myeloma cell population. Curr Top Microbiol Immunol, 1992;182201-7. PMID: 1490355
  11. Barlogie B. Pathophysiology of human multiple myeloma–recent advances and future directions. Curr Top Microbiol Immunol, 1992;182245-50. PMID: 1490361


  1. Barlogie B. Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin. Semin Hematol, 1993 Oct;30(4 Suppl 6);25-7. PMID: 8153675
  2. Barlogie B. Hemopoietic stem cell transplant for multiple myeloma (MM). Leukemia, 1993 Jul;7(7);1095. PMID: 8100602
  3. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood, 1993 Jun 15;81(12);3357-64. PMID: 8507873
  4. Vesole DH, Jagannath S, Glenn L, Barlogie B. Autotransplantation in multiple myeloma. Hematol Oncol Clin North Am, 1993 Jun;7(3);613-30. PMID: 8102136
  5. Barlogie B, Beck T. Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells, 1993 Mar;11(2);88-94. PMID: 8457789
  6. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood, 1993 Feb 1;81(3);767-74. PMID: 8427968


  1. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood, 1994 Nov 1;84(9);3063-70. PMID: 7949178
  2. Jagannath S, Vesole DH, Tricot G, Crowley J, Salmon SE, Barlogie B. Hemopoietic stem cell transplants for multiple myeloma. Oncology (Williston Park), 1994 Nov;8(11);89-103; discussion 103-6. PMID: 7826841
  3. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol, 1994 Nov;12(11);2405-14. PMID: 7964957
  4. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, Crowley J. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.Blood, 1994 Aug 1;84(3);950-6. PMID: 7913845
  5. Barlogie B, Vesole DH, Jagannath S. Salvage therapy for multiple myeloma: the University of Arkansas experience. Mayo Clin Proc, 1994 Aug;69(8);787-95. PMID: 8035638
  6. Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G. Deletion of the retinoblastoma gene in multiple myeloma. Leukemia, 1994 Aug;8(8);1280-4. PMID: 8057662
  7. Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol, 1994 Feb;21(2);350-2. PMID: 8182649
  8. Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin R. Limited value of myeloablative therapy for late multiple myeloma. Blood, 1994 Jan 15;83(2);512-6. PMID: 7904486
  9. Barlogie B, Jagannath S, Vesole D, Tricot G. Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma. J Hematother, 1994;3(2);149-53. PMID: 7922016
  10. Barlogie B, Crowley J, Salmon SE, Bonnet J, Weick JK, Hayden K. Phase II study of carboplatin (CBDCA) in refractory multiple myeloma. A Southwest Oncology Group study. Invest New Drugs, 1994;12(1);53-5.PMID: 7960607


  1. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 1995 Dec 1;86(11);4250-6.PMID: 7492784
  2. Epstein J, Hoover R, Kornbluth J, Barlogie B. Biological aspects of multiple myeloma. Baillieres Clin Haematol, 1995 Dec;8(4);721-34. PMID: 8845569
  3. Chen BP, Fraser C, Reading C, Murray L, Uchida N, Galy A, Sasaki D, Tricot G, Jagannath S, Barlogie B.Cytokine-mobilized peripheral blood CD34+Thy-1+Lin- human hematopoietic stem cells as target cells for transplantation-based gene therapy. Leukemia, 1995 Oct;9 Suppl 1S17-25. PMID: 7475307
  4. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 1995 Jul 15;86(2);685-91. PMID: 7605999
  5. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet, 1995 Jul 1;82(1);41-9. PMID: 7627933
  6. Gazitt Y, Reading CC, Hoffman R, Wickrema A, Vesole DH, Jagannath S, Condino J, Lee B, Barlogie B, Tricot G.Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood, 1995 Jul 1;86(1);381-9.PMID: 7540887
  7. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant, 1995 Jul;16(1);7-11. PMID: 7581132
  8. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood, 1995 Jan 15;85(2);588-96. PMID: 7529066
  9. Hoover RG, Lary C, Page R, Travis P, Owens R, Flick J, Kornbluth J, Barlogie B. Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16. J Clin Invest, 1995 Jan;95(1);241-7. PMID: 7529259
  10. Barlogie B, Jagannath S, Vesole D, Tricot G. Autologous and allogeneic transplants for multiple myeloma.Semin Hematol, 1995 Jan;32(1);31-44. PMID: 7878476
  11. Barlogie B, Hoover R, Epstein J. Multiple myeloma–recent developments in molecular and cellular biology.Curr Top Microbiol Immunol, 1995;19437-41. PMID: 7895511


  1. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B, Tricot G. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol, 1996 Nov;95(2);349-53. PMID: 8904891
  2. Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B.Autotransplants in multiple myeloma: what have we learned? Blood, 1996 Aug 1;88(3);838-47. PMID: 8704239
  3. Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, Vesole DH, Jagannath S, Meyers R, Barlogie B. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res, 1996 Jun;2(6);947-52. PMID: 9816255
  4. Tricot G, Jagannath S, Vesole DH, Bracy D, Desikan KR, Siegel D, Barlogie B. Hematopoietic stem cell transplants for multiple myeloma. Leuk Lymphoma, 1996 Jun;22(1-2);25-36. PMID: 8724525
  5. Grigoriev VG, Grigorieva I, Moerman EJ, Osborn CK, Epstein J, Crew MD. Senescent fibroblasts as feeder cells for lymphoid cell cloning. Anal Biochem, 1996 May 1;236(2);250-4. PMID: 8660501
  6. Chen BJ, Epstein J. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells.Blood, 1996 Mar 1;87(5);1972-6. PMID: 8634446
  7. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood, 1996 Feb 1;87(3);1196-8. PMID: 8562947
  8. Gazitt Y, Tian E, Barlogie B, Reading CL, Vesole DH, Jagannath S, Schnell J, Hoffman R, Tricot G. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood, 1996 Jan 15;87(2);805-11. PMID: 8555506
  9. Vesole DH, Jagannath S, Tricot G, Desikan KR, Siegel D, Barlogie B. Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma. Cancer Invest, 1996;14(4);378-91. PMID: 8689434
  10. Tricot GJ, Naucke S, Vaught L, Vesole D, Jagannath S, Barlogie B. Is the risk of multiple myeloma increased in patients with silicone implants? Curr Top Microbiol Immunol, 1996;210357-9. PMID: 8565577


  1. Barlogie B. Advances in therapy of multiple myeloma: lessons from acute leukemia. Clin Cancer Res, 1997 Dec;3(12 Pt 2);2605-13. PMID: 10068262
  2. Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol, 1997 Nov;99(2);368-71. PMID: 9375756
  3. Desikan KR, Dhodapkar MV, Hough A, Waldron T, Jagannath S, Siegel D, Barlogie B, Tricot G. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma, 1997 Oct;27(3-4);315-9. PMID: 9402328
  4. Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, Bracy D, Jones R, Crowley J, Tricot G, Barlogie B. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant, 1997 Sep;20(6);445-50. PMID: 9313876
  5. Guba SC, Vesole DH, Jagannath S, Bracy D, Barlogie B, Tricot G. Peripheral stem cell mobilization and engraftment in patients over age 60. Bone Marrow Transplant, 1997 Jul;20(1);1-3. PMID: 9232248
  6. Mehta J, Tricot G, Jagannath S, Desikan KR, Siegel D, Singhal S, Munshi N, Vesole D, Mattox S, Bracy D, Barlogie B. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplant, 1997 Jul;20(2);113-6. PMID: 9244413
  7. Singhal S, Mehta J, Barlogie B. Advances in the treatment of multiple myeloma. Curr Opin Hematol, 1997 Jul;4(4);291-7. PMID: 9260058
  8. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, Barlogie B.Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol, 1997 Jul;15(7);2659-66. PMID: 9215838
  9. Labardini-Méndez J, Alexanian R, Barlogie B. [Multiple myeloma and chronic lymphocytic leukemia] Rev Invest Clin, 1997 May;49 Suppl 128-33. PMID: 9380986
  10. Jagannath S, Tricot G, Barlogie B. Autotransplants in multiple myeloma: pushing the envelope. Hematol Oncol Clin North Am, 1997 Apr;11(2);363-81. PMID: 9137975
  11. Munshi NC, Govindarajan R, Drake R, Ding LM, Iyer R, Saylors R, Kornbluth J, Marcus S, Chiang Y, Ennist D, Kwak L, Reynolds C, Tricot G, Barlogie B. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood, 1997 Feb 15;89(4);1334-40. PMID: 9028956
  12. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 1997 Feb 1;89(3);789-93. PMID: 9028309
  13. Epstein J. Myeloma stem cell phenotype. Implications for treatment. Hematol Oncol Clin North Am, 1997 Feb;11(1);43-9. PMID: 9081203
  14. Barlogie B, Jagannath S, Epstein J, Munshi N, Siegel D, Desikan KR, Feinman R, Hsu PL, von Bremen K, Tricot G.Biology and therapy of multiple myeloma in 1996. Semin Hematol, 1997 Jan;34(1 Suppl 1);67-72. PMID: 9122748
  15. Siegel DS, Terry JA, Koury J, Barlogie B, Epstein J, Feinman R. Myc/max family of transcription factors and bcl-2 are involved in drug-induced apoptosis of myeloma cells. Curr Top Microbiol Immunol, 1997;224257-60. PMID: 9308249


  1. Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J, Siegel D, Shaughnessy J, Barlogie B.Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.Blood, 1998 Dec 1;92(11);4269-78. PMID: 9834233
  2. Thomas X, Anglaret B, Magaud JP, Epstein J, Archimbaud E. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. Leuk Lymphoma, 1998 Dec;32(1-2);107-19. PMID: 10037006
  3. Dhodapkar MV, Weinstein R, Tricot G, Jagannath S, Parfitt AM, Manolagas SC, Barlogie B. Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma, 1998 Dec;32(1-2);121-7. PMID: 10037007
  4. Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan KR, Perlman M, Munshi NC, Barlogie B. Anti-myeloma activity of pamidronate in vivo. Br J Haematol, 1998 Nov;103(2);530-2. PMID: 9827929
  5. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood, 1998 Oct 15;92(8);2908-13. PMID: 9763577
  6. Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol, 1998 Jul;26(7);597-603. PMID: 9657134
  7. Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, Fassas A, Tindle S, Nelson J, Juttner C, Tsukamoto A, Hallagan J, Atkinson K, Reading C, Hoffman R, Barlogie B. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood, 1998 Jun 15;91(12);4489-95. PMID: 9616143
  8. Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J, Tricot G, Alexanian R. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant, 1998 Jun;21(11);1101-7.PMID: 9645572
  9. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, Munshi N, Bracy D, Barlogie B, Butch AW.Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood, 1998 May 1;91(9);3518-23. PMID: 9558413
  10. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, Desikan K, Munshi N, Fassas A, Mattox S, Vesole D, Crowley J, Barlogie B. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant, 1998 May;21(9);887-92. PMID: 9613780
  11. Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B, Sanderson RD. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood, 1998 Apr 15;91(8);2679-88. PMID: 9531576
  12. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, Munshi N, Singhal S, Mehta J, Tindle S, Nelson J, Bracy D, Mattox S, Tricot G. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol, 1998 Apr;16(4);1547-53. PMID: 9552064
  13. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood, 1998 Mar 1;91(5);1732-41. PMID: 9473240
  14. Desikan KR, Jagannath S, Siegel D, Nelson J, Bracy D, Barlogie B, Tricot G. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma. Leuk Lymphoma, 1998 Feb;28(5-6);501-8. PMID: 9613979
  15. Barlogie B, Jagannath S, Tricot G, Desikan KR, Fassas A, Siegel D. Advances in the treatment of multiple myeloma. Adv Intern Med, 1998;43279-320. PMID: 9506186


  1. Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2. Cytokine, 1999 Dec;11(12);1010-9. PMID: 10623426
  2. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 1999 Nov 18;341(21);1565-71. PMID: 10564685
  3. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.Blood, 1999 Nov 15;94(10);3576-82. PMID: 10552969
  4. Munshi NC, Barlogie B, Desikan KR, Wilson C. Novel approaches in myeloma therapy. Semin Oncol, 1999 Oct;26(5 Suppl 13);28-34. PMID: 10528892
  5. Aslan T, Fassas AB, Desikan R, Siegel D, Munshi N, Mehta J, Singhal S, Barlogie B, Anaissie E. Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. Bone Marrow Transplant, 1999 Sep;24(5);505-9. PMID: 10482934
  6. Vesole DH, Crowley JJ, Catchatourian R, Stiff PJ, Johnson DB, Cromer J, Salmon SE, Barlogie B. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol, 1999 Jul;17(7);2173-9. PMID: 10561273
  7. Desikan KR, Dhodapkar MV, Munshi NC, Barlogie B. Recent advances in the treatment of multiple myeloma.Curr Opin Hematol, 1999 Jul;6(4);216-21. PMID: 10400369
  8. Singhal S, Mehta J, Desikan K, Siegel D, Singh J, Munshi N, Spoon D, Anaissie E, Ayers D, Barlogie B. Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-alpha therapy. Bone Marrow Transplant, 1999 Jul;24(1);13-7. PMID: 10435728
  9. Desikan R, Dhodapkar M, Siegel D, Fassas A, Singh J, Singhal S, Mehta J, Vesole D, Tricot G, Jagannath S, Anaissie E, Barlogie B, Munshi NC. High-dose therapy with autologous haemopoietic stem cell support for Waldenström’s macroglobulinaemia. Br J Haematol, 1999 Jun;105(4);993-6. PMID: 10554812
  10. Fassas AB, Desikan KR, Siegel D, Golper TA, Munshi NC, Barlogie B, Tricot G. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol, 1999 Jun;105(4);938-41. PMID: 10554803
  11. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood, 1999 May 1;93(9);3044-52. PMID: 10216101
  12. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, Anaissie E, Naucke S, Ayers D, Spoon D, Vesole D, Tricot G, Barlogie B. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood, 1999 Jan 1;93(1);51-4. PMID: 9864145
  13. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 1999 Jan 1;93(1);55-65. PMID: 9864146
  14. Fassas A, Jagannath S, Desikan KR, Shah HR, Shaver R, Waldron J, Munshi NC, Barlogie B, Tricot G.Lymphomatoid granulomatosis following autologous stem cell transplantation. Bone Marrow Transplant, 1999 Jan;23(1);79-81. PMID: 10037054
  15. Shaughnessy J, Barlogie B. Chromosome 13 deletion in myeloma. Curr Top Microbiol Immunol, 1999;246199-203. PMID: 10396057